ReviewClinical and experimental nephrology2019
Clinical and histological features and therapeutic strategies for IgA nephropathy.
Review in Clinical and experimental nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis.International urology and nephrology · 2023Pooled it
- Immunosuppressive agents for treating IgA nephropathy.The Cochrane database of systematic reviews · 2020Pooled it
- Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial.Scientific reports · 2022Trial
- Trial
- Bibliometric analysis of mucosal immunity in IgA nephropathy from 1990 to 2022.Immunity, inflammation and disease · 2024Article
- Mitochondrial DNA copy number in peripheral blood of IgA nephropathy: a cross-sectional study.Renal failure · 2023Article
- Iron metabolism and chronic inflammation in IgA nephropathy.Renal failure · 2023Review
- The Effects ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study.BMC nephrology · 2023Article
- Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis.BMC medical genomics · 2023Article
- Blind Spot in the Radar of MEST-C Score: Type and Severity of Tubulointerstitial Nephritis in IgA Nephropathy.International journal of nephrology · 2023Article
- A new pathological perspective on thrombotic microangiopathy.Kidney research and clinical practice · 2022Article
- The association of 5-year therapeutic responsiveness with long-term renal outcome in IgA nephropathy.Clinical and experimental nephrology · 2022Article
- A noninvasive artificial neural network model to predict IgA nephropathy risk in Chinese population.Scientific reports · 2022Article
- The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study.BMC nephrology · 2022Article
- Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis.Emergency medicine international · 2022Article
- A Novel Scoring System Based on Oxford Classification Indicating Steroid Therapy Use for IgA Nephropathy.Kidney international reports · 2022Article
- Rhein Inhibits NF-Applied bionics and biomechanics · 2022Article
- Mesangial Cell-Derived Exosomal miR-4455 Induces Podocyte Injury in IgA Nephropathy by Targeting ULK2.Oxidative medicine and cellular longevity · 2022Article
- Structural modeling for Oxford histological classifications of immunoglobulin A nephropathy.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic glomerulonephritis is the second most common reason, after diabetic nephropathy, for initiation of dialysis in Japan and IgA nephropathy (IgAN) is the most prevalent form of chronic glomerulonephritis. In the half century since IgAN was initially reported, our understanding of the long-term prognosis, clinical and histological features, pathogenesis of onset and progression, risk factors for progression, and appropriate treatment under different clinical and histological conditions, has steadily increased. Strong experimental and clinical evidence, the Clinical Practice Guidelines for IgA Nephropathy in Japan, the Oxford Classification, and the Kidney Disease Improving Global Outcomes guidelines have all contributed to the appropriate treatment of IgAN. Several intensive therapies, such as tonsillectomy, steroid therapy, and their combinations, can result in clinical remission, and prevent the progression to end stage renal disease (ESRD). However, some IgAN patients still progress to ESRD even when treated with intensive therapies. In this review, we discuss the clinical and histological features of IgAN, focusing primarily on our previous reports, and our opinions on therapeutic strategies for IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.